Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Assess a New Barrier Film's Ability to Provide Skin Protection Against Incontinence & Allow Healing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects may be enrolled into this study if the answers to all these questions are yes.~1. Is the subject a full-term newborn (36 weeks or greater gestational age) or older?~2. Is the subject in a facility providing nursing care 24 hours per day?~3. Does the subject have severe Category 2 Incontinence-Associated Dermatitis (IAD) -red with skin breakdown (i.e. skin erosion and denudation or denudation of skin alone)?~4. Is the subject willing to have photos taken of their skin exposed to incontinence and permit use of photographs in potential publication?~5. Is the subject willing to release rights to 3M for the use of the photos?~6. Is there a reasonable expectation that the subject will remain in a facility for at least 7 days following enrollment in the study?~7. Has the subject, or their legally authorized representative, signed an Institutional Review Board-approved informed consent/assent document and authorized the use and disclosure of protected health information?~Exclusion Criteria:~* Subjects are excluded from participation in this study if any of the answers to these following questions is yes.~  1. If female, is the subject pregnant or breast feeding or has she given birth within the 3 weeks preceding the screening visit?~ 2. Does the subject have a known allergy to acrylates or cyanoacrylates?~ 3. Does the subject have a Stage III, IV, unstageable, suspected deep tissue injury pressure ulcer in the area where the skin is affected by incontinence?~ 4. Does the subject have a preexisting skin disease on the areas affected by incontinence that may make skin assessments for this study difficult?~ 5. Does the skin area affected by incontinence require treatment with a concomitant medication or product?~ 6. Does the subject have an active genital herpes infection?~ 7. Has the subject received antifungal powders in the area affected with IAD within 24 hours prior to enrollment?~ 8. Has the subject received cyanoacrylate based skin protectant (such as Marathon) within 72 hours prior to enrollment?~ 9. Is the facility unwilling to discontinue use for this subject of Dimethicone-containing wipes on the area where the skin protectant product will be applied?~ 10. Is the facility unwilling to discontinue use for this subject of Chlorhexidine Gluconate wipes on the area where the skin protectant product will be applied?~ 11. Does the subject have any medical condition that in the opinion of the investigator should exclude him/her from participating in the study?~ 12. Has the subject been enrolled in any investigational study where product was applied to proposed study sites within 30 days of the screening visit?

- Gender: ALL
- Minimum Age: 1 Hour
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cavilon Advanced Skin Protectant (Type: EXPERIMENTAL): Product applicator contains liquid barrier applied on buttocks/thighs with it drying rapidly to durable barrier film. It's applied 3x/per week.
- ConvaTec Sensi-Care Protective Barrier (Type: ACTIVE_COMPARATOR): Marketed product applied following manufacturer's recommendation. The product is 15% zinc oxide with petrolatum.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy